Similar articles for PMID: 16724863

Year	Number of Results
1994	2
1995	1
1998	1
1999	1
2000	1
2001	1
2002	1
2004	2
2005	4
2006	6
2007	5
2008	3
2009	2
2010	3
2011	5
2012	11
2013	10
2014	13
2015	15
2016	12
2017	9
2018	7
2019	7
2020	8
2021	5
2022	0

1

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.

Dumont JA, Low SC, Peters RT, Bitonti AJ. Dumont JA, et al. BioDrugs. 2006;20(3):151-60. doi: 10.2165/00063030-200620030-00002. BioDrugs. 2006. PMID: 16724863 Review.

2

Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway.

Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, Stattel JM, Lu Y, Tan CA, Song JJ, Garcia AM, Simister NE, Spiekermann GM, Lencer WI, Blumberg RS. Bitonti AJ, et al. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9763-8. doi: 10.1073/pnas.0403235101. Epub 2004 Jun 21. Proc Natl Acad Sci U S A. 2004. PMID: 15210944 Free PMC article.

3

Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway.

Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP. Dumont JA, et al. J Aerosol Med. 2005 Fall;18(3):294-303. doi: 10.1089/jam.2005.18.294. J Aerosol Med. 2005. PMID: 16181004 Clinical Trial.

4

Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery.

Zhou L, Wang HY, Tong S, Okamoto CT, Shen WC, Zaro JL. Zhou L, et al. Biomaterials. 2017 Feb;117:24-31. doi: 10.1016/j.biomaterials.2016.11.051. Epub 2016 Nov 27. Biomaterials. 2017. PMID: 27923197

5

Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics.

Bajardi-Taccioli A, Blum A, Xu C, Sosic Z, Bergelson S, Feschenko M. Bajardi-Taccioli A, et al. Mol Immunol. 2015 Oct;67(2 Pt B):616-24. doi: 10.1016/j.molimm.2015.06.031. Epub 2015 Aug 5. Mol Immunol. 2015. PMID: 26254986

6

Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Suzuki T, et al. J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18. J Immunol. 2010. PMID: 20083659 Free article.

7

Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization.

Foss S, Grevys A, Sand KMK, Bern M, Blundell P, Michaelsen TE, Pleass RJ, Sandlie I, Andersen JT. Foss S, et al. J Control Release. 2016 Feb 10;223:42-52. doi: 10.1016/j.jconrel.2015.12.033. Epub 2015 Dec 21. J Control Release. 2016. PMID: 26718855

8

In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.

Shan L, Dyk NV, Haskins N, Cook KM, Rosenthal KL, Mazor R, Dragulin-Otto S, Jiang Y, Wu H, Dall'Acqua WF, Borrok MJ, Damschroder MM, Oganesyan V. Shan L, et al. Commun Biol. 2021 Sep 8;4(1):1048. doi: 10.1038/s42003-021-02565-5. Commun Biol. 2021. PMID: 34497355 Free PMC article.

9

Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway.

Bitonti AJ, Dumont JA. Bitonti AJ, et al. Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):1106-18. doi: 10.1016/j.addr.2006.07.015. Epub 2006 Aug 12. Adv Drug Deliv Rev. 2006. PMID: 16997417 Review.

10

Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.

Larsen MT, Rawsthorne H, Schelde KK, Dagnæs-Hansen F, Cameron J, Howard KA. Larsen MT, et al. J Control Release. 2018 Oct 10;287:132-141. doi: 10.1016/j.jconrel.2018.07.023. Epub 2018 Aug 29. J Control Release. 2018. PMID: 30016735

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed